Cargando…
To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars
ABSTRACT: In addition to the general clinical benefit offered, biosimilars may not only generate savings for healthcare budgets but also improve patient access to biologic products. Since the first biosimilar was approved in Europe in 2006, a further 36 different biosimilar drugs have been approved...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096951/ https://www.ncbi.nlm.nih.gov/pubmed/29873005 http://dx.doi.org/10.1007/s12325-018-0719-8 |